Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects

Psychiatry Res. 1991 Sep;38(3):227-36. doi: 10.1016/0165-1781(91)90013-f.

Abstract

Ten healthy male subjects were administered i.v. meta-chlorophenylpiperazine (MCPP) (0.1 mg/kg) after oral ritanserin (5-10 mg), a putative 5HT1c/5HT2 (serotonin) antagonist, or placebo. Behavioral responses, cardiovascular effects, and neuroendocrine responses (cortisol, growth hormone, and prolactin) were measured serially for 4 hours after MCPP infusion. Premedication with ritanserin attenuated the MCPP-induced increases in self-rated anxiety and prolactin, and completely antagonized MCPP cortisol elevations. In contrast, ritanserin did not significantly alter growth hormone response to MCPP. These findings suggest a role for 5-HT1c/5-HT2 receptors in the endocrine and behavioral responses to the mixed serotonin agonist MCPP in humans.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • Anxiety / metabolism
  • Data Interpretation, Statistical
  • Double-Blind Method
  • Growth Hormone / drug effects
  • Growth Hormone / isolation & purification
  • Humans
  • Hydrocortisone / isolation & purification
  • Hydrocortisone / metabolism
  • Male
  • Personality Inventory
  • Piperazines / administration & dosage*
  • Placebos
  • Prolactin / drug effects
  • Prolactin / isolation & purification
  • Receptors, Serotonin / drug effects*
  • Ritanserin / administration & dosage*

Substances

  • Piperazines
  • Placebos
  • Receptors, Serotonin
  • Ritanserin
  • Prolactin
  • Growth Hormone
  • 1-(3-chlorophenyl)piperazine
  • Hydrocortisone